S&P 500 Technology Sector SEC Filings — March 13, 2026

13-03-2026

13-03-2026

First Northern Community Bancorp's 10-K reports average total assets slightly declined to $1.89B in 2025 from $1.89B in 2024, while average loans remained nearly flat at $1.05B with yields improving to 5.53% from 5.30%. Net interest income rose 4.8% to $67.5M with margin expanding to 3.77% from 3.60%; however, demand deposits fell 7.3% to $650M and time certificates declined 7.7% to $141M. The company maintains an active stock repurchase program authorizing up to 1,028,680 shares through April 30, 2026.

• ·Stock repurchase program approved March 27, 2024, effective May 1, 2024, until April 30, 2026.
• ·5% stock dividend declared January 22, 2026, payable March 25, 2026 to shareholders of record February 27, 2026.

13-03-2026

AC Immune SA filed its 20-F annual report on March 13, 2026, disclosing a May 2024 worldwide license agreement with Takeda for active immunotherapies targeting Abeta, including ACI-24.060, with potential option exercise fee in the low-to-mid nine-figure USD range, up to $2.1B in milestones, and royalties from low-double digits to mid-teens. However, as a clinical-stage biopharmaceutical company, it reports a history of losses, anticipates future losses without additional funding, low clinical success probabilities in CNS, insufficient patent terms risks, and potential PFIC status impacting U.S. investors.

• ·Likely PFIC for previous taxable years; believes not PFIC for 2025 but no assurance, uncertain for 2026+
• ·Risk of insufficient patent terms to protect products
• ·No product revenues expected for several years due to low CNS clinical success probabilities

13-03-2026

Adient plc held its 2026 Annual General Meeting on March 10, 2026, where shareholders elected eight directors with overwhelming majorities (For votes ranging 60.9M to 61.9M shares), ratified PricewaterhouseCoopers LLP as auditors for FY2026 (65.0M For), approved named executive officer compensation (58.4M For), and renewed board authorities to issue shares and opt-out of preemption rights. Separately, the Board approved a $500,000 Special RSU retention award for Executive Vice President James Conklin, vesting one-half per year over two years.

• ·Special RSU Award grant date: May 7, 2026; vests subject to continued service, with protections for involuntary termination without cause, death, or disability.
• ·Proposal 1 Against votes ranged 206K-1.16M shares; Proposal 2 Against: 1.47M shares; Proposal 3 Against: 3.65M shares; Proposal 4 Against: 487K shares; Proposal 5 Against: 2.73M shares.
• ·Special RSU Agreement filed as Exhibit 10.42 to 10-K on November 18, 2024.

13-03-2026

Verizon Communications Inc. revised its revenue reporting presentation for Verizon Consumer Group and Verizon Business Group segments, disaggregating into mobility and broadband service revenue, wireless equipment revenue, and other revenue starting in Q1 2026. The company also changed operating metrics disclosure to consolidated basis only going forward. As a convenience, unaudited historical financial and operating information reflecting these changes is provided in Exhibit 99.

• ·Information furnished under Item 7.01 is not deemed filed with SEC
• ·Securities listed on NYSE and Nasdaq Global Select Market

13-03-2026

Esquire Financial Holdings, Inc. reported net income of $50.8M or $5.87 per diluted share for the year ended December 31, 2025, achieving ROAA of 2.43% and ROAE of 19.41%. Balance sheet totals included $2.37B in assets, $1.76B in loans, $2.06B in deposits, and $289.6M in stockholders' equity, with noninterest income of $25.1M representing 17% of total revenue driven by payment processing and ASP fees. However, the company highlighted risks related to completing its pending merger with Signature Bancorporation, Inc., including integration challenges and regulatory approvals.

• ·Litigation-Related Loans consist of WC LOC (66.2%), Case Cost LOC (17.7%), and term loans to law firms (15.8%).
• ·Average contingency case litigation timeframe: 2-4 years.
• ·Pending merger with Signature requires shareholder and regulatory approvals, with integration risks for assets, liabilities, systems, personnel, customers, synergies, and potential goodwill charges.

13-03-2026

Ducommun Incorporated (DCO) filed Definitive Additional Proxy Soliciting Materials (DEFA14A) on March 13, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing includes proxy statement details for shareholder solicitation, with no financial metrics, performance data, or period comparisons disclosed.

• ·Fiscal year end: December 31
• ·Business address: 600 Anton Boulevard, Suite 1100, Costa Mesa, CA 92626
• ·EIN: 95-0693330
• ·Standard Industrial Classification: Aircraft Part & Auxiliary Equipment, NEC [3728]

13-03-2026

Applied Materials, Inc. held its Annual Meeting of Shareholders on March 12, 2026, electing all ten director nominees with strong majorities (for votes ranging from 536,089,076 to 597,000,433; against votes up to 62,101,403 for Kevin P. March). Shareholders approved on an advisory basis the FY2025 named executive officer compensation (552,486,796 for, 41,457,649 against) and ratified KPMG LLP as independent auditor for FY2026 (636,399,482 for, 46,823,436 against). All three proposals passed decisively, with consistent broker non-votes of 85,096,891 across director elections.

• ·Annual Meeting held on March 12, 2026; filing dated March 13, 2026
• ·Proposal 2 approval advisory for FY2025 executive compensation
• ·Proposal 3 ratification for KPMG LLP as auditor for FY2026
• ·Broker non-votes: 85,096,891 for all director proposals

13-03-2026

Salesforce, Inc. completed a registered public offering of $25B aggregate principal amount of senior notes on March 13, 2026, consisting of eight series maturing between 2028 and 2066 with fixed interest rates ranging from 4.500% to 6.700% per year, payable semi-annually starting September 15, 2026. The net proceeds are being used to repurchase shares of the company's common stock pursuant to accelerated share repurchase agreements. The notes are unsecured senior debt ranking equally with other unsubordinated obligations, with customary redemption and default provisions.

• ·Notes mature on: March 15, 2028 (2028/2029/2033/2036/2046/2056 Notes); September 15, 2031 (2031 Notes); March 15, 2066 (2066 Notes).
• ·Company may redeem notes at applicable redemption price as described in Third Supplemental Indenture.
• ·Events of default include payment failures, covenant breaches, and bankruptcy; acceleration possible by trustee or 25% holders.

13-03-2026

On March 12, 2026, Optimum Communications, Inc.'s Compensation Committee approved deferred cash awards (DCAs) valued at a total of $9.375M to four key executives as part of the 2026 long-term incentive program (LTIP), with CEO Dennis Mathew receiving $5M, CFO Marc Sirota $1.75M, General Counsel Michael Olsen $1.5M, and President Michael Parker $1.125M. The DCAs represent 50% of the 2026 LTIP (replacing prior restricted stock units), while overall LTIP targets, salaries, and short-term incentive targets remain unchanged from 2025; short-term bonuses will now be assessed and paid quarterly rather than annually. Vesting occurs one-third on December 14 of 2026, 2027, and 2028, subject to continued service.

• ·DCAs qualified by reference to form of DCA agreement to be filed as exhibit to Form 10-Q for quarter ending March 31, 2026
• ·Company securities: Class A Common Stock, par value $0.01 per share (OPTU on NYSE)

13-03-2026

Intuitive Surgical, Inc.'s DEF 14A proxy statement for the 2026 Annual Meeting on April 30, 2026, discloses a leadership transition appointing Dave Rosa as CEO and Gary S. Guthart, Ph.D. as Executive Chair following a robust succession process. Proposals include electing 10 directors (with 8 independent nominees), advisory approval of NEO compensation, ratification of PricewaterhouseCoopers LLP as auditors for FY 2026, and amending the 2010 Incentive Award Plan. The company emphasizes strong governance practices, including a lead independent director and engagement with stockholders representing 45% of outstanding shares as of December 31, 2025.

• ·Record Date: March 2, 2026
• ·Annual Meeting: Virtually online at www.virtualshareholdermeeting.com/ISRG2026
• ·Board recommendations: FOR all four proposals
• ·100% of Board committee members are independent
• ·Proxy materials mailing starts on or about March 17, 2026

13-03-2026

MultiSensor AI Holdings, Inc. entered into an At Market Issuance Sales Agreement on March 13, 2026, with Roth Capital Partners, LLC and H.C. Wainwright & Co., LLC, enabling the sale of up to $60M in common stock through at-the-market offerings. Proceeds, if any, will fund working capital and general corporate purposes, with agents earning up to a 3.0% commission. The agreement follows an amendment on March 12, 2026, to the company's October 24, 2025 Securities Purchase Agreement to allow the offering.

• ·Sales Agreement utilizes shelf registration on Form S-3 (File No. 333-284437), effective January 30, 2025.
• ·Offering terminates upon sale of all shares or termination by parties.
• ·Company is an emerging growth company.

13-03-2026

Aditxt, Inc. (NASDAQ: ADTX) acquired Ignite Proteomics, LLC, a commercial-stage precision oncology company with a functional proteomics platform (RPPA) for therapy selection in cancer care, by issuing 36,000 shares of Series A-2 Convertible Preferred Stock valued at $36M. Ignite targets a $3B serviceable market opportunity amid a $14B global cancer profiling market, operates a CLIA-certified lab with Medicare PLA reimbursement of ~$2,200 per test, and plans a 2026 program for 600,000+ US metastatic cancer patients. The deal strengthens Aditxt's oncology portfolio through Ignite's validated platform and collaborations with institutions like Dana-Farber and Inova Health.

• ·Ignite's platform validated via I-SPY 2 data and presented at 2025 NCCN Conference, showing MHC-II expression outperforming PD-L1 assays for pembrolizumab response.
• ·September 2025 collaboration with Inova Health incorporates RPPA data into Molecular Tumor Board for late-stage GI cancers lacking standard biomarkers.
• ·Ongoing clinical validation with NCI-designated centers including Dana-Farber at Harvard and Vanderbilt.
• ·Ignite operates CLIA-certified, CAP-accredited laboratory.

13-03-2026

Chemung Financial Corp's 2025 annual results showed net income declining 36.2% YoY to $15.1M from $23.7M, driven by a 65.8% drop in non-interest income to $7.9M due to a $17.5M loss on securities sales and a $4.4M provision for credit losses versus a $46k credit in 2024. However, net interest income rose 17.7% YoY to $87.2M with net interest margin expanding to 3.26% from 2.76%, fueled by commercial loan growth and lower deposit costs. Adjusted for nonrecurring items, net income increased 17.8% to $27.9M, while asset quality improved with non-performing loans at 0.35% of total loans (down from 0.43%) and ROE at 6.40% (unadjusted decline from 11.53%).

• ·Commercial loans average balance increased to $1.61B in 2025 from $1.45B in 2024 (+11.0% YoY).
• ·Consumer loans average balance declined to $261M in 2025 from $295M in 2024 (-11.5% YoY).
• ·Taxable securities average balance dropped to $444M from $613M (-27.7% YoY).
• ·Loans to deposits ratio rose to 99.95% from 86.42%.
• ·Total equity to total assets improved to 9.40% from 7.76%.
• ·Net charge-offs increased to $1.9M from $1.2M.

13-03-2026

NorthEast Community Bancorp, Inc. (NECB) reported net income of $44.4M for the year ended December 31, 2025, down 5.65% YoY from $47.1M, driven by a 2% decline in net interest income to $100.7M and lower yields on interest-earning assets (8.04% vs. 8.75%), with net interest margin contracting to 5.25% from 5.62%. Total average assets grew 4.7% to $2.01B, supported by 6.1% loan growth to $1.81B average balance, while non-interest expenses rose 9.2% to $42.7M; however, non-interest income surged 47% to $4.1M and non-performing assets improved to $0 from $5.1M. Return on average equity declined to 13.12% from 15.59%.

• ·Provision for credit losses was a reversal of $99K in 2025 vs. $740K provision in 2024.
• ·Salaries and employee benefits increased to $23.2M from $20.9M.
• ·No non-accrual loans or accruing loans past due 90 days in either year.

13-03-2026

The AllianceBernstein National Municipal Income Fund, Inc. filed Definitive Additional Proxy Materials (DEFA14A) on March 13, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing includes metadata such as the company's address at AllianceBernstein LP, 66 Hudson Boulevard East, 26th Floor, New York, NY 10001, fiscal year end of October 31, and SEC file number 811-10573. No financial results, performance metrics, or substantive proxy details are discernible in the provided content, which consists primarily of headers, graphics, and encoded data.

• ·Fiscal year end: October 31
• ·SEC file number: 811-10573
• ·Former company name: ALLIANCE NATIONAL MUNICIPAL INCOME FUND (name change date: November 8, 2001)
• ·Business phone: 212-969-2124

13-03-2026

RideNow Group, Inc. reported total revenue of $1,082.5M in 2025, down 10.5% YoY from $1,209.2M, primarily due to declines in powersports vehicles revenue (-7.6%), parts/service/accessories (-4.1%), finance/insurance (-5.0%), and a sharp drop in vehicle transportation services (-85.2%). Gross profit decreased 5.2% to $298.0M, though powersports gross profit per retail vehicle improved 5.1% to $5,208 and same-store powersports gross profit rose 2.8% to $283.9M. SG&A expenses fell 6.9% to $256.3M, but new retail vehicle units sold declined 9.4% to 38,459.

• ·Floor plan interest expense declined 31.3% to $11.0M.
• ·Depreciation and amortization decreased 37.1% to $9.0M.
• ·Impairment of intangible assets fell 11.5% to $34.8M.
• ·Wholesale vehicles sold increased 18.1% to 5,019 units, but revenue per wholesale vehicle dropped 41.3%.
• ·Same store new retail vehicles revenue declined 8.2%, but gross profit per new vehicle rose 16.6%.